At a glance
ClinicalIndex Comparison Record- ✓Age <70 years
- ✓Advanced multiple myeloma (stage II/III at diagnosis, or stage I with progression/failure to respond)
- ✓Eligible for mobilization/debulking with Cytoxan/VP-16/G-CSF, Cytoxan/Taxol/G-CSF, or Cytoxan/G-CSF per protocol 506.03, or prior adequate PBSC collection
- ✓For syngeneic donation: donor and patient documented as syngeneic (ABO typing, HLA typing, VNTR studies); donor >20 kg; donor meets eligibility per Standard Practice Guidelines
- ✕Age ≥70 years
- ✕Karnofsky score <80
- ✕Left ventricular ejection fraction <50%, or history of congestive heart disease, MI, coronary artery disease, or arrhythmia
- ✕Total bilirubin >1.5 mg/mL (unless Gilbert's disease history)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunotherapy for Autologous/Syngeneic Peripheral Blood Stem Cell (PBSC) Transplant Patients as Treatment for Advanced Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating melphalan, recombinant interferon alfa, and 2 other interventions for Refractory Multiple Myeloma and 3 related conditions. Completed, enrolled 36 participants across 1 site.
Detailed Summary
This phase II trial studies the effectiveness of melphalan, peripheral stem cell transplantation, and interleukin-2 followed by interferon alfa in treating patients who have advanced multiple myeloma (MM). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Interleukin-2 (IL2) may stimulate a person's white blood cells to kill multiple myeloma cells. Interferon alfa may interfere with the growth of cancer cells
Study Details
Timeline
Interventions
Given IV
Given SC
Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion